A superior substance P antagonist with high potency and negligible neurotoxicity. More effective than spantide II.
Product Details
| Sequence: | N-ε-Nicotinoyl-D-Lys-Pro-3-Pyridyl-Ala-Pro-D-Cl2Phe-Asn-D-Trp-Phe-D-3-Pyridyl-Ala-Leu-Nle-NH2 |
| |
| MW: | 1630.8 |
| |
| Source: | Synthetic. |
| |
| Formulation: | Lyophilized. |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White to off-white powder. |
| |
| Solubility: | Soluble in Water. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Atrophy of submandibular gland by the duct ligation and a blockade of SP receptor in rats: S. Hishida, et al.; Nagoya J. Med. Sci.
78, 215 (2016),
Application(s): Injected into submandibular rat glands,
Abstract;
Full Text
Spantide III, a superior tachykinin antagonist with high potency and negligible neurotoxicity: K. Folkers, et al.; Amino Acids
5, 233 (1993),
Abstract;
